Merck KGaA (MRK) Given a €108.00 Price Target by Kepler Capital Markets Analysts
Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA (FRA:MRK) in a research report report published on Thursday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other equities research analysts also recently weighed in on the company. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the stock a buy rating in a report on Thursday. Oddo Bhf set a €100.00 ($116.28) target price on Merck KGaA and gave the stock a neutral rating in a report on Wednesday. Nord/LB set a €80.00 ($93.02) target price on Merck KGaA and gave the stock a sell rating in a report on Wednesday. Warburg Research set a €103.00 ($119.77) target price on Merck KGaA and gave the stock a neutral rating in a report on Wednesday. Finally, Goldman Sachs Group set a €95.00 ($110.47) target price on Merck KGaA and gave the stock a neutral rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have assigned a buy rating to the stock. Merck KGaA has a consensus rating of Hold and an average price target of €98.00 ($113.95).
Shares of MRK traded up €4.14 ($4.81) during midday trading on Thursday, reaching €97.64 ($113.53). 779,281 shares of the stock were exchanged. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: What are the components of an earnings report?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.